| scholarly article | Q13442814 |
| P356 | DOI | 10.1677/JOE.0.1740233 |
| P698 | PubMed publication ID | 12176662 |
| P2093 | author name string | D Hörsch | |
| A Trümper | |||
| K Trümper | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| P304 | page(s) | 233-246 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Journal of Endocrinology | Q6295150 |
| P1476 | title | Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells | |
| P478 | volume | 174 |
| Q33541007 | A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control |
| Q34540961 | A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents |
| Q35942505 | A simple matter of life and death-the trials of postnatal Beta-cell mass regulation |
| Q35055522 | Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass |
| Q37980541 | Alogliptin benzoate for the treatment of type 2 diabetes |
| Q34620671 | Alogliptin: a new addition to the class of DPP-4 inhibitors |
| Q35043520 | Alterations of glucose-dependent insulinotropic polypeptide and expression of genes involved in mammary gland and adipose tissue lipid metabolism during pregnancy and lactation |
| Q38724829 | An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice |
| Q33224640 | Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). |
| Q36321851 | Bicarbonate-responsive "soluble" adenylyl cyclase defines a nuclear cAMP microdomain |
| Q36579507 | Cocaine- and amphetamine-regulated transcript (CART) protects beta cells against glucotoxicity and increases cell proliferation |
| Q51746108 | Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. |
| Q38285608 | DPP-4 inhibitors: focus on safety |
| Q38292782 | Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP. |
| Q43149045 | Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut. |
| Q40324361 | Downregulation of protein kinase B/Akt-1 mediates INS-1 insulinoma cell apoptosis induced by dominant-negative suppression of hepatocyte nuclear factor-1alpha function |
| Q38301976 | Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. |
| Q35843905 | Effects of High Glucose Levels and Glycated Serum on GIP Responsiveness in the Pancreatic Beta Cell Line HIT-T15. |
| Q97539390 | Effects of an enzymatically stable analogue of the gut-derived peptide xenin on beta-cell transdifferentiation in high fat fed and insulin-deficient Ins1Cre /+ ;Rosa26-eYFP mice |
| Q54483237 | Effects of selenium and exendin-4 on glucagon-like peptide-1 receptor, IRS-1, and Raf-1 in the liver of diabetic rats. |
| Q45114419 | Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. |
| Q36990110 | Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin |
| Q35545683 | Enhancing Incretin Action for the Treatment of Type 2 Diabetes |
| Q33609502 | GIP and GLP-1, the two incretin hormones: Similarities and differences |
| Q58448374 | GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet |
| Q47970022 | Gastrointestinal Peptides During Chronic Gastric Electrical Stimulation in Patients With Intractable Vomiting |
| Q37805600 | Gastrointestinal hormones and the regulation of β-cell mass |
| Q55215413 | Genetic Variability of the Glucose-Dependent Insulinotropic Peptide Gene Is Involved in the Premature Coronary Artery Disease in a Chinese Population with Type 2 Diabetes. |
| Q38517852 | Genomic profiling of cortical neurons following exposure to beta-amyloid. |
| Q34401791 | Glucagon-like peptide 1(GLP-1) in biology and pathology |
| Q40592531 | Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells |
| Q40132400 | Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function |
| Q51817062 | Glucose-Dependent Insulinotropic Peptide Prevents Serum Deprivation-Induced Apoptosis in Human Bone Marrow-Derived Mesenchymal Stem Cells and Osteoblastic Cells. |
| Q40437409 | Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and dow |
| Q37403983 | Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). |
| Q36342463 | Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. |
| Q44286265 | Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. |
| Q33987816 | Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells. |
| Q28572231 | Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2 |
| Q37911549 | Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders |
| Q38108631 | Incretin hormones and beta-cell mass expansion: what we know and what is missing? |
| Q40180167 | Inhibition of GSK3 promotes replication and survival of pancreatic beta cells |
| Q57805706 | Inhibition of TBK1/IKKε Promotes Regeneration of Pancreatic β-cells |
| Q51369351 | Insulin modulates glucose-dependent insulinotropic polypeptide (GIP) secretion from enteroendocrine K cells in rats. |
| Q39881169 | Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. |
| Q37969863 | Nutrient detection by incretin hormone secreting cells |
| Q28304006 | Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells |
| Q45009703 | Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1 |
| Q26766485 | Pancreatic regulation of glucose homeostasis |
| Q33983473 | Postnatal development of numbers and mean sizes of pancreatic islets and beta-cells in healthy mice and GIPR(dn) transgenic diabetic mice |
| Q37604464 | Protein hydrolysates in sports nutrition |
| Q42105494 | RETRACTED: Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment |
| Q36693199 | Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus |
| Q53207032 | Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. |
| Q40223208 | Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. |
| Q64904804 | Reprogramming Cells to Make Insulin. |
| Q41766825 | Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide |
| Q37091579 | Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins |
| Q82427245 | The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats |
| Q37889275 | The emerging role of the intestine in metabolic diseases |
| Q30365939 | The entero-insular axis: implications for human metabolism. |
| Q33776092 | The incretin system and cardiometabolic disease |
| Q35251016 | The role of gut hormones in glucose homeostasis |
| Q34901533 | The role of incretins in glucose homeostasis and diabetes treatment |
| Q37779101 | Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? |
| Q33580451 | Transcriptional analysis of apoptotic cerebellar granule neurons following rescue by gastric inhibitory polypeptide |
| Q83079212 | [Early improvement in Type 2 diabetes in obese patients following gastric bypass and bilio-pancreatic diversion: the role of the entero-insular axis] |
Search more.